Pharmaceuticals
Frost & Sullivan Recognizes Allscripts as a Growth and Innovation Leader in the United States Healthcare Data Interoperability Market
Allscripts enables enterprise-level, interoperability-aided EMR workflow adjustments and the subsequent clinical decision-making from a single window SANTA CLARA, Calif., Oct. 7, 2020 /PRNewswire/ -- Frost & Sullivan has identified Allscripts, a global healthcare IT company, as a growth and inno...
2020-10-07 18:02
3565
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period
SAN FRANCISCO and SUZHOU, China, Oct. 7, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major dis...
2020-10-07 08:00
14400
First Commercial Drug Manufactured via Ajinomoto Bio-Pharma Services' AJIPHASE Technology Receives FDA Approval
TOKYO, Oct. 6, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the US FDA has approved the first commercial drug manufactured via Aji Bio-Pharma's proprietar...
2020-10-06 22:20
3304
Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis
- Merck out-licenses promising clinical-stage program to Novartis - Anti-ADAMTS5 Nanobody® program is Phase II-ready with novel MoA which could protect against cartilage damage and reduce joint pain - Merck receives upfront payment of € 50 million with the potential of receiving a further € 400...
2020-10-06 20:00
3077
Results Evaluating The Effect Of Ubiquinol On Endothelial Function Published In Nutrients
PASADENA, Texas, Oct. 6, 2020 /PRNewswire/ -- Kaneka Nutrients today announced the results of an 8-week, randomized, double-blind, single-center trial, demonstrating health benefits of Ubiquinol on endothelial function and antioxidant protection. This study was designed to measure change in flow...
2020-10-06 01:33
2211
Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 30, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II clinical trials of Batoclimab (HBM 9161), a fully human...
2020-09-30 21:50
5463
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China Center for Drug Evaluation (CDE) has app...
2020-09-30 20:00
11793
The 11th China (Taizhou) International Medical Expo ended successfully
NANJING, China, Sept. 30, 2020 /PRNewswire/ -- From September 19 to 21, the 11th China (Taizhou) International Medical Expo was held at the China Medical City Exhibition Center. With the theme of "Development Trends in the Medical and Health Industry under the Epidemic", the current medical expo h...
2020-09-30 19:52
1710
TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand
TAIPEI, Sept. 30, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen")(Taiwan: 4157) today announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® ...
2020-09-30 15:51
1859
Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology
STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North:LIPI) today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The study was conducted in collabor...
2020-09-30 15:44
3051
Data Science to Accelerate Drug Discovery with Artificial Intelligence and Machine Learning, Says Frost & Sullivan
Pharmaceutical companies and hospitals are adopting data science rapidly, and its application is going to be established in all branches of healthcare SANTA CLARA, Calif., Sept. 29, 2020 /PRNewswire/ -- Frost & Sullivan's recent analysis,Data Science Impacting the Pharmaceutical Industry, finds t...
2020-09-29 22:10
3046
Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic
OSAKA, Japan, Sept. 29, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a ...
2020-09-29 20:01
2716
VolitionRx Limited Announces Virtual Capital Markets Day 2020
AUSTIN, Texas, Sept. 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases, today announced it will host a capital market...
2020-09-29 20:00
9715
Daewoong Pharmaceutical's new SGLT2 inhibitor for diabetes treatment demonstrates remarkable effect in phase 2 clinical trial
SEOUL, South Korea, Sept. 29, 2020 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) announced the result of its phase 2 trial on enavogliflozin, a novel SGLT2 inhibitor, for the first time at the 2020 International Congress of Diabetes and Metabolism (ICDM) held on Sep. 18–19. ...
2020-09-29 15:00
2065
Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...
2020-09-28 12:13
5611
Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. In this secondary listing, the issue price is HK$5...
2020-09-28 11:26
5457
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
* New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced * Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standar...
2020-09-28 06:00
2587
Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study
* New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced * Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat, in a gold-standar...
2020-09-28 04:00
5582
Salonpas becomes Title Sponsor of Pulse Active's HCMC Marathon for the next 3 years
HO CHI MINH CITY, Vietnam, Sept. 25, 2020 /PRNewswire/ -- First held in 2013, HCMC Marathon is one of the largest and longest-standing marathon races in Vietnam, which has attracted over 51,000 runners across the world to participate in the last 7 years. The organizer of the race, Pulse Active is ...
2020-09-25 18:36
3856
Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- -Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menari...
2020-09-25 18:15
7177
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
